Navigation Links
Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis

ing research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of drugs for cancer and transplantation and a market leader in virology. In 2006, sales by the Pharmaceuticals Division totaled 33.3 billion Swiss franc ($26.6 billion US), and the Diagnostics Division posted sales of 8.7 billion Swiss franc ($6.96 billion US). Roche employs roughly 75,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Additional information, about the Roche Group is available on the Internet at http://www.roche.com.

All trademarks used or mentioned in this release are protected by law.

This news release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward-looking information within the meaning of applicable securities laws in Canada (collectively, "forward-looking statements"). The words "anticipates", "believes", "budgets", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "projects", "schedule", "should", "will", "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this news release include, but are not limited to, statements about: our strategy, future operations, clinical trials, prospects and plans of management; the effects of CellCept on patients; our expectations with respect to our existing collaboration agreement with Roche for the dev
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:2/27/2015)... 27, 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" or ... announced financial results for its first quarter ended December ... ended December 31, 2014, revenue was $1,336,685. Operating expenses ... or $0.02 per share.  Covalon,s President ... very pleased with the significant progress we have made ...
(Date:2/27/2015)... SAN DIEGO , Feb. 27, 2015 /PRNewswire/ ... three-dimensional biology company focused on delivering breakthrough 3D ... , President and Chief Executive Officer, will present ... "We invite you to join us for ... to provide updates on our commercial launch of ...
(Date:2/27/2015)... MINNEAPOLIS , Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: ... develops, manufactures and markets innovative proprietary products to treat ... the 27th Annual ROTH Conference on Tuesday, March 10, ... Brett Reynolds , Chief Financial Officer, will present ... one on one at the conference at the Ritz ...
Breaking Medicine Technology:Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Uroplasty to Participate in the 27th Annual ROTH Conference 2
... Technology is revolutionizing healthcare — making it more ... cost of care. AT&T ,s* new set of ... designed to do just that. The 2011 Frost & ... AT&T for its approach to mHealth, recognizing the company,s ...
... -- GC-Rise Pharmaceutical Co. Ltd, in which European healthcare ... recently listed as one of the Deloitte & Touche,s ... growth over the past three years. Beijing-headquartered ... its operating revenues rising more than 270% on average ...
Cached Medicine Technology:Frost and Sullivan Recognizes AT&T's Innovative mHealth Strategy 2Frost and Sullivan Recognizes AT&T's Innovative mHealth Strategy 3Frost and Sullivan Recognizes AT&T's Innovative mHealth Strategy 4Women Health Expert GC-Rise Listed in Deloitte's 50 Top-performing Companies 2
(Date:3/2/2015)... 02, 2015 ProvidaStaff has ... its educational healthcare division to EDU Healthcare ... services to school systems and students nationwide. , “ProvidaStaff ... school districts throughout the country,” said Angela M. Lewis, ... a better organization and the introduction of EDU Healthcare ...
(Date:3/2/2015)... 02, 2015 Final Cut Pro X ... Volume 2 from Pixel Film Studios. , “The TranStatic Volume ... FCPX,” said Christina Austin, CEO of Pixel Film Studios. “TranStatic ... Final Cut Pro X editors toolbox.” , With TranStatic Volume ... with media altering static scrambling effects from Pixel Film Studios. ...
(Date:3/1/2015)... Clearwater, Florida (PRWEB) March 02, 2015 ... market their services and manage their practices ... offer an integrated all-inclusive solution. The ... development program and a medical practice management ... success and long-term financial sustainability. A referral ...
(Date:3/1/2015)... As residents and business owners in Southlake, Texas, ... Weaver, believe in supporting local organizations and causes. ... of Commerce, Carroll Independent School District and numerous ... for Southlake mayoral candidate Laura Hill: http://www.LauraHillforSouthlake.com ... campaign, the website combines images, videos and interactive ...
(Date:3/1/2015)... Birmingham, Clarkston, Lake Orion, Metamora, Michigan (PRWEB) March 01, 2015 ... BOTOX® , which is approved to treat Overactive Bladder (OAB) ... urgency and frequency in adults when another type of medication ... This is a different treatment option that takes another ... itself. , BOTOX® works on the nerves and ...
Breaking Medicine News(10 mins):Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 3Health News:Pixel Film Studios released the TranStatic Volume 2 plugin for Final Cut Pro X today 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 3Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 4Health News:Website Launched for Southlake, Texas Mayoral Candidate Laura Hill 2Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2
... New England Journal of Medicine reports the latest research ... crossed in treating early breast //cancer successfully after having ... studies apparently looked into the effectiveness of adding the ... in early stages of breast cancer. Both studies ...
... Breast Cancer Campaign charity yesterday suggested that breast cancer may ... a long-term manageable disorder like diabetes and arthritis. ... to the significant developments in the diagnosis and treatment of ... recurrence of the cancer was reduced by new drugs like ...
... less inclined to commit suicide as compared to Whites was ... among black Americans. Scientists from the University of Michigan said ... ones own life happens to be the 11th leading cause ... that nearly one in 10 black Americans suffer from suicidal ...
... of coffee (3 cups a day) can affect a man's ... to show the adverse effect of modern life on the ... the US govt. has shown that modern men have only ... hampster (160 million/ml). The sperm count has declined worldwide over ...
... More than two-thirds of people who suffer from major ... work with their doctors //and try various treatments to ... taking different antidepressants or adding cognitive therapy to the ... led by UT Southwestern Medical Center, found that 67 ...
... According to British scientists, symptoms of schizophrenia can be ... Imperial College London conducted a study in 4 hospitals ... when they were encouraged to express themselves through music. ... psychological treatments can help people with schizophrenia, but these ...
Cached Medicine News:Health News:Breast Cancer may no longer be a killer disease 2Health News:Carefully Monitored Treatment Can Help Those Who Suffer from Depression 2Health News:Carefully Monitored Treatment Can Help Those Who Suffer from Depression 3
... Bausch & Lomb PreserVision® AREDS formula ... and mineral supplement clinically proven effective in ... Age Related Eye Disease Study (AREDS). , ... and mineral supplement with the antioxidant vitamins ...
Ocuvite® vitamin and mineral supplements contain 2 mg of Lutein 8 times more than the leading multivitamins. Ocuvite also contains vitamin antioxidants A, C and E, as well as the minerals zinc, ...
HydroEye is an exclusive formulation designed to provide dry eye relief and support the body's natural tear formation. Like all ScienceBased Health formulations, it is produced in softgel form for ma...
Easy-to-use desktop QC data management solution...
Medicine Products: